A recent European trial (MOSAIC) has documented significant improvement in 3-year disease-free survival when oxaliplatin (Eloxatin) was added to infusional 5-FU and leucovorin in the FOLFOX regimen.
Continuous infusion 5-FU: patient handout from scotland
cost of various chemoregimens: what is in store for the future if we start looking at cost/benefit ratios?
patient's blog on experience with treatment for colon cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment